002262 Stock Overview
Engages in production, marketing, and services related to central nervous system drugs in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
Jiangsu Nhwa Pharmaceutical Co., LTD Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥22.37 |
| 52 Week High | CN¥29.98 |
| 52 Week Low | CN¥20.36 |
| Beta | 0.011 |
| 1 Month Change | -0.80% |
| 3 Month Change | -1.19% |
| 1 Year Change | -3.41% |
| 3 Year Change | 94.18% |
| 5 Year Change | 63.52% |
| Change since IPO | 1,201.90% |
Recent News & Updates
Recent updates
Jiangsu Nhwa Pharmaceutical Co., LTD's (SZSE:002262) Prospects Need A Boost To Lift Shares
Feb 08
Is Now The Time To Put Jiangsu Nhwa Pharmaceutical (SZSE:002262) On Your Watchlist?
Jan 21We Think Jiangsu Nhwa Pharmaceutical (SZSE:002262) Can Manage Its Debt With Ease
Jan 01Jiangsu Nhwa Pharmaceutical Co., LTD (SZSE:002262) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Oct 28Is Now The Time To Put Jiangsu Nhwa Pharmaceutical (SZSE:002262) On Your Watchlist?
Oct 21Jiangsu Nhwa Pharmaceutical (SZSE:002262) Has A Rock Solid Balance Sheet
Sep 20The Market Doesn't Like What It Sees From Jiangsu Nhwa Pharmaceutical Co., LTD's (SZSE:002262) Earnings Yet
Sep 04Here's Why Jiangsu Nhwa Pharmaceutical (SZSE:002262) Has Caught The Eye Of Investors
Jul 22Jiangsu Nhwa Pharmaceutical (SZSE:002262) Seems To Use Debt Rather Sparingly
Jun 16Jiangsu Nhwa Pharmaceutical Co., LTD's (SZSE:002262) Share Price Is Matching Sentiment Around Its Earnings
May 09Jiangsu Nhwa Pharmaceutical (SZSE:002262) Ticks All The Boxes When It Comes To Earnings Growth
Apr 18Earnings Update: Jiangsu Nhwa Pharmaceutical Co., LTD (SZSE:002262) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts
Apr 02Shareholder Returns
| 002262 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 1.2% | 3.6% | 2.7% |
| 1Y | -3.4% | 3.7% | 7.7% |
Return vs Industry: 002262 underperformed the CN Pharmaceuticals industry which returned 3.7% over the past year.
Return vs Market: 002262 underperformed the CN Market which returned 7.7% over the past year.
Price Volatility
| 002262 volatility | |
|---|---|
| 002262 Average Weekly Movement | 4.8% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 7.0% |
| 10% most volatile stocks in CN Market | 10.7% |
| 10% least volatile stocks in CN Market | 4.3% |
Stable Share Price: 002262 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 002262's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1978 | 5,923 | Jiaquan Sun | www.nhwa-group.com |
Jiangsu Nhwa Pharmaceutical Co., LTD engages in production, marketing, and services related to central nervous system drugs in China. It’s product portfolio includes Duloxetine Hcl, Risperidone, Ziprasidone Hcl, Etomidate Fat Emulsion, Gabapentin, Zaleplon, etc.; and Iptakalim, an anti-hypertension drug. The company’s products are used for treatment of anesthesiology, psychiatry and neurology, as well as APIs.
Jiangsu Nhwa Pharmaceutical Co., LTD Fundamentals Summary
| 002262 fundamental statistics | |
|---|---|
| Market cap | CN¥22.52b |
| Earnings (TTM) | CN¥1.14b |
| Revenue (TTM) | CN¥5.70b |
19.9x
P/E Ratio4.0x
P/S RatioIs 002262 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 002262 income statement (TTM) | |
|---|---|
| Revenue | CN¥5.70b |
| Cost of Revenue | CN¥1.55b |
| Gross Profit | CN¥4.15b |
| Other Expenses | CN¥3.01b |
| Earnings | CN¥1.14b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Apr 19, 2025
| Earnings per share (EPS) | 1.13 |
| Gross Margin | 72.87% |
| Net Profit Margin | 20.07% |
| Debt/Equity Ratio | 0.2% |
How did 002262 perform over the long term?
See historical performance and comparisonDividends
1.6%
Current Dividend Yield32%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/17 11:54 |
| End of Day Share Price | 2025/04/17 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Jiangsu Nhwa Pharmaceutical Co., LTD is covered by 21 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yanyin Zhu | China International Capital Corporation Limited |
| Shanshan Li | China Merchants Securities Co. Ltd. |
| Ling Bo Tu | China Minzu Securities |